18F-FDG PET in children with lymphomas

Depas, Gisèle; Barsy, Caroline De; Jérusalem, Guy; Hoyoux, Claire; Dresse, Marie-Françoise; Fassotte, Marie-France; Paquet, Nancy; Foidart, Jacqueline; Rigo, Pierre; Hustinx, Roland

doi:10.1007/s00259-004-1604-z

Cited by 110 publications

(44 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of the present work are presented in tables (1)(2)(3)(4)(5)(6)(7)(8)(9) The sensitivities and specificities of 18F-FDG PET/CT for initial staging of malignant lymphomas were ranged 83.3%-100% and 93.75%-100% respectively. They ranged 66.70%-100% and 91.30%-100% respectively in STS and 86.70%-100% and 95.80%-100% respectively in Neuroblastoma.The negative and positive predictive valuesin evaluating the stage of lymphoma were 93.30%-100% and 40.00%-100% respectively.…”

Section: Results:-mentioning

confidence: 96%

Evaluation of PET/CTRole in Diagnosis and Management of Pediatric Malignancy

A¹,

G.²

2017

IJAR

View full text Add to dashboard Cite

Section: Results:-mentioning

confidence: 96%

Evaluation of PET/CTRole in Diagnosis and Management of Pediatric Malignancy

A¹,

G.²

2017

IJAR

View full text Add to dashboard Cite

“…Pediatric malignancies are regarded as distinct from adult malignancies in view of their low frequency, treatment strategy, and expected prognosis (8,16). Special attention should be required in interpreting images of pediatric patients, taking these conditions into consideration.…”

Section: Discussionmentioning

confidence: 99%

“…However, only a limited number of reports have been available to date on noncentral nervous system (CNS) body malignancies in pediatric patients with FDG PET (4)(5)(6)(7)(8), likely due to the relative infrequency of pediatric malignancies and limited insurance coverage. Thallium ( 201 Tl), gallium ( 67 Ga), metaiodobenzylguanidine, and bone scintigaphies are often used to evaluate pediatric body malignancies, in addition to CT, ultrasound, radiography, and MRI.…”

mentioning

confidence: 99%

18F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies

Tatsumi

Miller

Wahl³

2007

Journal of Nuclear Medicine

View full text Add to dashboard Cite

We reviewed our experience of 18 F-FDG PET/CT in noncentral nervous system (CNS) pediatric malignancies and evaluated if PET/CT provided additional information to conventional imaging (CI) examinations to determine the efficacy of this new imaging modality in the clinical setting. Methods: One-hundred fiftyone consecutive FDG PET/CT examinations in 55 pediatric patients with non-CNS malignant tumors were reviewed. Among them, 108 PET/CT examinations were accompanied by CI, such as contrast CT or MRI, performed within a month of PET/ CT in our hospital. Two radiologists reviewed the indication, purpose, and PET/CT findings and compared the findings with those of CI, if available, on the representative lesion in each of the 6 separate body regions. Positive findings included abnormal findings related to malignant lesions (suspected) as well as equivocal findings, in which the presence of malignancy could not be denied, but excluded findings considered to relate to past treatment. Accuracy of the findings was determined on the basis of the reference standard comprising histopathologic findings or informative follow-up of .1 y. An examination-based analysis was also performed in terms of additional information of PET/CT to CI. Results: There were 56 PET/CT-positive-CI-positive, 26 PET/ CT-positive-CI-negative, and 54 PET/CT-negative-CI-positive lesions in 108 PET/CT examinations accompanied by CI, of which 54, 20, and 52 exhibited accurate PET/CT findings, respectively. Seventeen of the 20 PET/CT true-positive-CI falsenegative lesions represented small lymph nodes diagnosed as negative on CI. All 52 PET/CT true-negative-CI false-positive findings were observed in lesions in a posttreatment status including 30 mediastinal masses in lymphoma. Examinationbased analysis revealed that additional information of PET/CT to CI was found in 37 (34%) of the 108 examinations: 23 (21%) as negative and 14 (13%) as positive PET/CT findings. Conclusion: PET/CT exhibited better diagnostic performance than CI and showed accurate findings in 90% (72/80) of lesions with discordant findings between them. Additional information of PET/ CT to CI was observed in more than one third of examinations compared. PET/CT was demonstrated to be an accurate imaging modality in evaluating pediatric patients with non-CNS malignancies.

show abstract

“…In NHL patients, Yang et al reported that a persistent tumor 18 F-FDG uptake on interim 18 F-FDG PET/CT scans predicted worse overall survival and event-free survival (54). However, this principle may not hold for all types of NHL (38,43). A recent study on nonlymphoblastic lymphoma patients showed that neither interim 18 F-FDG PET/CT nor interim CT scans could predict survival (38).…”

Section: Therapy Response Assessmentmentioning

confidence: 99%

“…Several investigators reported, for both pediatric HL and pediatric NHL, that additional information obtained on 18 F-FDG PET scans compared with CT scans changed management in up to 32% of patients (20,42,43). The most frequent management impact was avoiding radiotherapy of soft-tissue masses in HL, which did not show significant hypermetabolism on 18 F-FDG PET scans at the end of therapy.…”

Section: Therapy Response Assessmentmentioning

confidence: 99%

Value of¹⁸F-FDG PET and PET/CT for Evaluation of Pediatric Malignancies

et al. 2015

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to (1) understand the current status of the role of 18 F-FDG PET and PET/CT for staging and treatment monitoring of pediatric malignancies; (2) discuss the limitations of 18 F-FDG PET and PET/CT for pediatric cancer imaging; and (3) discuss areas of pediatric cancer imaging in which further studies are needed.

show abstract

18F-FDG PET in children with lymphomas

Abstract: 18F-FDG-PET is a useful tool for evaluating children with lymphomas. Large prospective studies are needed to appreciate its real impact on patient management.

Cited by 110 publications

References 21 publications

Evaluation of PET/CTRole in Diagnosis and Management of Pediatric Malignancy

Evaluation of PET/CTRole in Diagnosis and Management of Pediatric Malignancy

18F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies

Value of¹⁸F-FDG PET and PET/CT for Evaluation of Pediatric Malignancies

Contact Info

Product

Resources

About

18F-FDG PET in children with lymphomas

Abstract: 18F-FDG-PET is a useful tool for evaluating children with lymphomas. Large prospective studies are needed to appreciate its real impact on patient management.

Cited by 110 publications

References 21 publications

Evaluation of PET/CTRole in Diagnosis and Management of Pediatric Malignancy

Evaluation of PET/CTRole in Diagnosis and Management of Pediatric Malignancy

18F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies

Value of18F-FDG PET and PET/CT for Evaluation of Pediatric Malignancies

Contact Info

Product

Resources

About

Value of¹⁸F-FDG PET and PET/CT for Evaluation of Pediatric Malignancies